

2022 NRG Oncology Presentation Schedule

Advancing Research. Improving Lives.

Oral, Quick Pitch Oral, Poster, and Educational Presentations

OCTOBER 23 - 26, 2022

Disease Site & Study #	Sunday, October 23, 2022	Time/Location
GI-Esophagus NRG/RTOG 1010	<p>Title: <i>Patient-reported outcomes (PROs) in NRG Oncology RTOG 1010: phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing (HER2+) esophageal adenocarcinoma (EAC).</i></p> <p>Presenter: Lisa A Kachnic, MD</p> <p>Abstract #: 117</p> <p>*GI Highlights session, 10/26/22 at 8:00am CT, Room 007A/B</p>	<p>Location: Room 301</p> <p>Session: SS 04 - GI 1 - Esophageal Cancers: The Pros and Cons of Combined Modality Therapy</p> <p>Date/Time: Oct 23, 4:45PM-6:00PM</p> <p>Duration: 10 minutes</p> <p>Oral</p>
Lung SWOG/NRG S1914	<p>Title: <i>SWOG/NRG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT vs. SBRT Alone in High Risk, Early-Stage NSCLC (NCT#04214262).</i></p> <p>Presenter: Megan E Daly, MD</p> <p>Abstract #: 2925</p>	<p>Location: Exhibit Hall 1</p> <p>Session: PQA 01 - Poster Q&A 01 - Lung Cancer and DEIH</p> <p>Date/Time: Oct 23, 4:45PM-6:00PM</p> <p>Poster</p>
Disease Site & Study #	Monday, October 24, 2022	Time/Location
Breast NRG/RTOG 1005	<p>Title: <i>NRG RTOG 1005: A Phase III Trial of Hypo fractionated Whole Breast Irradiation with Concurrent Boost Versus Conventional Whole Breast Irradiation plus Sequential Boost following Lumpectomy for High Risk Early-Stage Breast Cancer.</i></p> <p>Presenter: Frank A Vicini, MD</p> <p>Abstract #: 1</p>	<p>Location: Stars at Night Ballroom</p> <p>Session: Plenary Session</p> <p>Date/Time: Oct 24, 1:30 PM</p> <p>Duration: 10 Minutes</p> <p>Plenary</p>
GU-Prostate NRG/RTOG 9202, NRG/RTOG 9408, NRG/RTOG 9413, NRG/RTOG 9910, NRG/RTOG 0126	<p>Title: <i>Prostate cancer risk stratification in NRG Oncology phase III randomized trials using multi-modal deep learning with digital histopathology.</i></p> <p>Presenter: Jonathan D Tward, MD</p> <p>Abstract #: 2</p>	<p>Location: Stars at Night Ballroom</p> <p>Session: Plenary Session</p> <p>Date/Time: Oct 24, 1:40 PM</p> <p>Duration: 10 Minutes</p> <p>Plenary</p>
GI-Non-Colorectal NRG/RTOG 1112	<p>Title: <i>NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937).</i></p> <p>Presenter: Laura A Dawson, MD</p> <p>Abstract #: 52345</p>	<p>Location: Stars at Night Ballroom</p> <p>Session: Plenary Session</p> <p>Date/Time: Oct 24, 1:50 PM</p> <p>Duration: 10 Minutes</p> <p>Plenary</p>
Head and Neck NRG-HN004	<p>Title: <i>Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004.</i></p> <p>Presenter: Loren K Mell, MD</p> <p>Abstract #: 52495</p>	<p>Location: Stars at Night Ballroom</p> <p>Session: Plenary Session</p> <p>Date/Time: Oct 24, 2:00 PM</p> <p>Duration: 10 Minutes</p> <p>Plenary</p>

GU-Prostate NRG/ROG 0534	Title: <i>The influence of pelvic lymph node dissection volumes on clinical outcomes in NRG/ROG 0534.</i> Presenter: William A Hall, MD Abstract #: 158	Location: Room 214 Session: SS 11 - GU 2 - New Insights into Post-Prostatectomy Radiotherapy Date/Time: Oct 24, 3:20 PM Duration: 10 minutes Oral
Disease Site & Study #	Tuesday, October 25, 2022	Time/Location
GU-Prostate NRG/ROG 1115	Title: <i>RTOG/NRG 1115 quality of life of phase III dose escalated radiation therapy (RT) & standard androgen deprivation therapy (ADT) with GnRH agonist vs. dose escalated RT & ADT with GnRH agonist and orteronel (TAK-700) for men with high-risk prostate cancer.</i> Presenter: Deborah W Bruner, MD Abstract #: 2477	Location: Exhibit Hall 1 Session: PQA 06 - Poster Q&A 06 - Genitourinary Cancer, Patient Safety, and Nursing Date/Time: Oct 25, 2:30 PM-3:45 PM Poster
GU-Prostate NRG/ROG 1115	Title: <i>Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with TAK-700 for men with high-risk prostate cancer (NRG Oncology/ROG 1115).</i> Presenter: Dror Michaelson, MD Abstract #: 220	Location: Hemisfair Ballroom C1 Session: SS 22- GU 4 - Improving Outcome for High-Risk Prostate Cancer Date/Time: Oct 25, 4:10 PM Duration: 10 minutes Oral
GU-Bladder INTACT SWOG/NRG 1806	Title: <i>INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients.</i> Presenter: Sameer G Jhavar, MD, PhD Abstract #: 237	Location: Hemisfair Ballroom C1 Session: SS 25 - GU 5 - Bladder and Kidney Preservation Date/Time: Oct 25, 5:45 PM Duration: 7 minutes Oral
Brain NRG-CC001	Title: <i>Evaluating the Utility of EQ5D-5L in Patients with Brain Metastases: Secondary Analysis of NRG-CC001.</i> Presenter: H Ryan Cherng, MD Abstract #: 189	Location: Room 007 C/D Session: SS 17 - PRO 1 - Incorporating the Patient Voice: A Session Focused on PROs and Survivorship Date/Time: Oct 25, 12:55 PM Duration: 7 minutes Oral
Disease Site & Study #	Wednesday, October 26, 2022	Time/Location
Head and Neck NRG/ROG 0522	Title: <i>A retrospective analysis of NRG/ROG 0522: low myofibroblast content in the tumor-associated stroma may predict response to epidermal growth factor receptor (EGFR) inhibitors.</i> Presenter: Yoseful Haque, MD Abstract #: 2647	Location: Exhibit Hall 1 Session: PQA 09 - Poster Q&A 09 - Head & Neck Cancer and Health Services Research Date/Time: Oct 26, 10:30 AM-11:45 AM Poster
Head & Neck NRG/ROG 0129, NRG/ROG 0522, NRG/ROG 1016	Title: <i>Gastrostomy tube use in head and neck cancer survivors: Pre-treatment factors supersede treatment intensification. A second analysis of RTOG 0129, RTOG 0522, and NRG/ROG 1016.</i> Presenter: Thomas J Galloway, MD Abstract #: 282	Location: Room 214 Session: SS 33 - H&N 3 - Toxicity Mitigation and HPV-Unrelated Head and Neck Cancer - Life Beyond De-Intensification Date/Time: Oct. 26, 1:00 PM Duration: 10 minutes Oral

Disease Site & Study #	The following presentations include NRG data from the NCTN Data Archive or Data Sharing	Time/Location
Sunday, October 23, 2022		
GU-Prostate NRG/RTOG 0126, NRG/RTOG 0415	Title: <i>Conditional Survival of Patients with Prostate Cancer Undergoing External-Beam Radiotherapy on RTOG 0126 and 0415.</i> Presenter: Gregory S Alexander, MD Abstract #: 1003	Location: Room 304 Session: QP 01 - GU 1 - Improving Prostate Cancer Survival Date/Time: Oct 23, 8:05 AM Duration: 5 minutes Oral
Lung NRG/RTOG 0617	Title: <i>Explainable Artificial Intelligence for Identification of Dosimetric Predictors of Radiation Toxicity: A Secondary Analysis of RTOG 0617.</i> Presenter: Colton J Ladbury, MD Abstract #: 1007	Location: Room 304 Session: QP 02 - DHI 1 - Individualizing Treatment Using AI: Opportunities and Challenges Date/Time: Oct 23, 4:55 PM Duration: 5 minutes Oral
Lung NRG Oncology Multi Lung	Title: <i>Disparities in Racial and Ethnic Enrollment and Reporting: An Analysis of Reported NRG Radiation Oncology Trials.</i> Presenter: Colton J Ladbury, MD Abstract #: 2296	Location: Exhibit Hall Session: PQA 01 - Poster Q&A 01 - Lung Cancer and DEIH Date/Time: Oct 23, 4:45 PM-6:00 PM Poster
Tuesday, October 25, 2022		
Lung NRG/RTOG 0617	Title: <i>Explainable Boosting Machine for Choosing Radiation Dose-Volume Constraints on Cardio-Pulmonary Substructures Associated with Overall Survival in the NRG Oncology RTOG 0617 Clinical Trial.</i> Presenter: Sang Ho Lee, PhD Abstract #: 178	Location: Room 008 Session: SS 15 - DHI 3 - Leveraging AI to Strengthen Clinical Decision Frameworks Date/Time: Oct 25, 8:10 AM Duration: 7 minutes Oral
Lung NRG/RTOG 0617	Title: <i>Left Anterior Descending Coronary Artery Radiation Dose Association with All-Cause Mortality in NRG Oncology Trial RTOG 0617.</i> Presenter: Elizabeth McKenzie, PhD Abstract #: 201	Location: Hemisfair Ballroom C1 Session: SS 19 - Lung 2 - Optimizing Thoracic RT Planning and Reducing Treatment Toxicity Date/Time: Oct 25, 12:45 PM Duration: 7 minutes Oral
GU-Prostate NRG/RTOG 0126, NRG/RTOG 0415	Title: <i>Toxicity Analysis of Patients with Prostate Cancer Treated with 3D-Conformal Compared to Intensity Modulated Radiotherapy: Secondary Analysis of RTOG 0126 and RTOG 0415.</i> Presenter: Rebecca F Krc, DO Abstract #: 2508	Location: Exhibit Hall 1 Session: PQA 06 - Poster Q&A 06 - Genitourinary Cancer, Patient Safety, and Nursing Date/Time: Oct 25, 2:30 PM-3:45 PM Poster